{"id":1435629,"date":"2012-05-02T08:35:47","date_gmt":"2012-05-02T06:35:47","guid":{"rendered":"https:\/\/staging-wp-int.laboklin.com\/anti-mullerian-hormone\/"},"modified":"2024-07-24T13:24:35","modified_gmt":"2024-07-24T11:24:35","slug":"anti-mullerian-hormone","status":"publish","type":"post","link":"https:\/\/laboklin.com\/dk\/anti-mullerian-hormone\/","title":{"rendered":"Anti-Mullerian Hormone"},"content":{"rendered":"

[vc_row][vc_column width=”2\/3″][vc_column_text]<\/p>\n

– Differentiation: Castrated, Uncastrated or Cryptorchid<\/h2>\n

– Diagnosis of Granulosa Cell Tumours in Mares<\/h2>\n
\n

The Anti-M\u00fcllerian Hormone (AMH) is a glycoprotein that plays an important role in the sex differentiation during embryogenesis.<\/p>\n

In male animals testosterone is responsible for the development of the Wolffian ducts, whereas AMH is needed to prevent the development of the mullerian ducts into the uterus and other mullerian structures.<\/p>\n

In female animals AMH is not produced by the gonads during sex differentiation in early gestation, so the mullerian ducts automatically develop and the normal development of the female genitals occurs. In female animals, AMH is expressed by granulosa cells of the ovary controlling the formation of primary follicles by inhibiting excessive follicular recruitment by FSH.<\/p>\n

Horse<\/h2>\n

In human medicine AMH is used to diagnose Granulosa cell tumours (GCT) (Fig. 1). As GCT is the most frequent diagnosed tumour of the equine female genitals (~85% of tumours found in the reproductive organs), it was obvious to try to establish this diagnostic test for mares as well. This idea was presented by B. A. Ball et al., at the AAEP Annual Convention in November 2011, which presented equine results. They had successfully been able to establish and validate a human test also for horses.<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column][vc_column width=”1\/3″][vc_column_text]<\/p>\n\n\t\t\t